Scandinavian ChemoTech AB Series B (CMOTEC-B) - Total Assets
Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) holds total assets worth Skr17.38 Million SEK (≈ $1.87 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Scandinavian ChemoTech AB Series B (CMOTEC-B) net assets for net asset value and shareholders' equity analysis.
Scandinavian ChemoTech AB Series B - Total Assets Trend (2013–2024)
This chart illustrates how Scandinavian ChemoTech AB Series B's total assets have evolved over time, based on quarterly financial data.
Scandinavian ChemoTech AB Series B - Asset Composition Analysis
Current Asset Composition (December 2024)
Scandinavian ChemoTech AB Series B's total assets of Skr17.38 Million consist of 58.1% current assets and 41.9% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 7.1% |
| Accounts Receivable | Skr3.51 Million | 26.3% |
| Inventory | Skr3.31 Million | 24.7% |
| Property, Plant & Equipment | Skr4.00K | 0.0% |
| Intangible Assets | Skr5.44 Million | 40.7% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Scandinavian ChemoTech AB Series B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Scandinavian ChemoTech AB Series B.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scandinavian ChemoTech AB Series B's current assets represent 58.1% of total assets in 2024, a decrease from 100.0% in 2013.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2024, down from 100.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 40.7% of total assets.
Scandinavian ChemoTech AB Series B Competitors by Total Assets
Key competitors of Scandinavian ChemoTech AB Series B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Scandinavian ChemoTech AB Series B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.17 | 1.48 | 0.62 |
| Quick Ratio | 0.86 | 0.86 | 0.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr1.96 Million | Skr2.75 Million | Skr-2.57 Million |
Scandinavian ChemoTech AB Series B - Advanced Valuation Insights
This section examines the relationship between Scandinavian ChemoTech AB Series B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.45 |
| Latest Market Cap to Assets Ratio | 0.76 |
| Asset Growth Rate (YoY) | -10.0% |
| Total Assets | Skr13.38 Million |
| Market Capitalization | $10.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scandinavian ChemoTech AB Series B's assets below their book value (0.76x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scandinavian ChemoTech AB Series B's assets decreased by 10.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scandinavian ChemoTech AB Series B (2013–2024)
The table below shows the annual total assets of Scandinavian ChemoTech AB Series B from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr13.38 Million ≈ $1.44 Million |
-10.01% |
| 2023-12-31 | Skr14.87 Million ≈ $1.60 Million |
-31.48% |
| 2022-12-31 | Skr21.70 Million ≈ $2.34 Million |
-15.92% |
| 2021-12-31 | Skr25.81 Million ≈ $2.78 Million |
+61.40% |
| 2020-12-31 | Skr15.99 Million ≈ $1.72 Million |
-8.57% |
| 2019-12-31 | Skr17.49 Million ≈ $1.88 Million |
-23.32% |
| 2018-12-31 | Skr22.81 Million ≈ $2.45 Million |
+77.58% |
| 2017-12-31 | Skr12.84 Million ≈ $1.38 Million |
-23.67% |
| 2016-12-31 | Skr16.83 Million ≈ $1.81 Million |
+152.93% |
| 2015-12-31 | Skr6.65 Million ≈ $715.95K |
+9995.57% |
| 2014-12-31 | Skr65.90K ≈ $7.09K |
+48.40% |
| 2013-12-31 | Skr44.41K ≈ $4.78K |
-- |
About Scandinavian ChemoTech AB Series B
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian Che… Read more